EVANSTON, Ill., March 20, 2007 /PRNewswire/ -- Treatment of coronary artery disease (CAD) appears to be shifting away from the inpatient setting, according to a study published today in The American Journal of Cardiology.
U.S. hospitalization rates for heart attacks (acute myocardial infarctions) declined 10.6 percent from 2002 to 2005, possibly due to broader use of preventive treatments such as statin drugs and aspirin, as well as declines in risk factors like smoking.
The study is a collaboration between researchers from the University of Michigan Medical School and Solucient, part of Thomson Healthcare, a leading provider of information and solutions to improve the cost and quality of healthcare.
"Although there was an expectation that the aging U.S. population would cause an increased need for inpatient care of patients with cardiovascular disease, the reality is that changes in treatment may be causing a shift to the outpatient setting," said Janet Young, M.D., a senior scientist at Solucient. "This trend has important implications for hospitals and health systems and their allocation of resources."
Researchers found that: - Hospitalizations for acute myocardial infarction (AMI) decreased steadily from 661,000 in 2002 to 591,000 in 2005 -- a decline from 309 to 266 per 100,000 persons. This was driven by a decrease in the more severe transmural form of AMI from 118 to 87 per 100,000. - Hospitalization rates for coronary revascularization declined from 382 to 358 per 100,000 persons from 2002 to 2005 -- largely due to a decrease in coronary artery bypass surgeries from 258,000 to 209,000 per year. - During this period, inpatient use of less-invasive revascularization treatments known as percutaneous coronary interventions -- including the use of balloon angioplasty and stents administered via cardiac catheterization -- increased from 5
Page: 1 2 3
Related medicine technology :
1. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
2. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
3. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
4. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
5. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
6. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
7. Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of Lialda (mesalamine) Presented at DDW
8. New Study Demonstrates that Lubiprostone May Improve Symptom Relief Rates in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)
9. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
10. Preterm Infants with Respiratory Distress Syndrome: Incidence Rates of Death when Treated with Surfactant Replacement Therapies
11. Over 10,000 UK Breast Cancer Patients Could Become Eligible Within the Next Year for a Breast Cancer Therapy Showing Increased Survival Rates, Reveals Synovate Healthcare’s European Oncology Monitor